These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 26758422)

  • 41. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
    Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
    Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.
    Batlevi CL; Kasamon Y; Bociek RG; Lee P; Gore L; Copeland A; Sorensen R; Ordentlich P; Cruickshank S; Kunkel L; Buglio D; Hernandez-Ilizaliturri F; Younes A
    Haematologica; 2016 Aug; 101(8):968-75. PubMed ID: 27151994
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma.
    Ramalingam SS; Belani CP; Ruel C; Frankel P; Gitlitz B; Koczywas M; Espinoza-Delgado I; Gandara D
    J Thorac Oncol; 2009 Jan; 4(1):97-101. PubMed ID: 19096314
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).
    Cashen A; Juckett M; Jumonville A; Litzow M; Flynn PJ; Eckardt J; LaPlant B; Laumann K; Erlichman C; DiPersio J
    Ann Hematol; 2012 Jan; 91(1):33-8. PubMed ID: 21538061
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma.
    Havas AP; Rodrigues KB; Bhakta A; Demirjian JA; Hahn S; Tran J; Scavello M; Tula-Sanchez AA; Zeng Y; Schmelz M; Smith CL
    Cancer Biol Ther; 2016 Dec; 17(12):1240-1252. PubMed ID: 27791595
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study.
    Ribrag V; Kim WS; Bouabdallah R; Lim ST; Coiffier B; Illes A; Lemieux B; Dyer MJS; Offner F; Felloussi Z; Kloos I; Luan Y; Vezan R; Graef T; Morschhauser F
    Haematologica; 2017 May; 102(5):903-909. PubMed ID: 28126962
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ofatumumab monotherapy in relapsed/refractory diffuse large B-cell non-Hodgkin lymphoma.
    Galanina N; Jasielec J; Peace D; Smith SM; Nabhan C
    Leuk Lymphoma; 2017 Mar; 58(3):752-753. PubMed ID: 27415580
    [No Abstract]   [Full Text] [Related]  

  • 48. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.
    DeAngelo DJ; Spencer A; Bhalla KN; Prince HM; Fischer T; Kindler T; Giles FJ; Scott JW; Parker K; Liu A; Woo M; Atadja P; Mishra KK; Ottmann OG
    Leukemia; 2013 Aug; 27(8):1628-36. PubMed ID: 23385375
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology.
    Shah RR
    Drug Saf; 2019 Feb; 42(2):235-245. PubMed ID: 30649740
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
    Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
    Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.
    Straus DJ; Hamlin PA; Matasar MJ; Lia Palomba M; Drullinsky PR; Zelenetz AD; Gerecitano JF; Noy A; Hamilton AM; Elstrom R; Wegner B; Wortman K; Cella D
    Br J Haematol; 2015 Mar; 168(5):663-70. PubMed ID: 25316653
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma.
    Vacirca JL; Acs PI; Tabbara IA; Rosen PJ; Lee P; Lynam E
    Ann Hematol; 2014 Mar; 93(3):403-9. PubMed ID: 23955074
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis.
    Hong JY; Yoon DH; Suh C; Kim WS; Kim SJ; Jo JC; Kim JS; Lee WS; Oh SY; Park Y; Kim SY; Lee MH; Lee HS; Do YR
    Ann Hematol; 2018 Aug; 97(8):1437-1443. PubMed ID: 29619501
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma.
    Evens AM; Balasubramanian S; Vose JM; Harb W; Gordon LI; Langdon R; Sprague J; Sirisawad M; Mani C; Yue J; Luan Y; Horton S; Graef T; Bartlett NL
    Clin Cancer Res; 2016 Mar; 22(5):1059-66. PubMed ID: 26482040
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma.
    Higashi M; Tokuhira M; Fujino S; Yamashita T; Abe K; Arai E; Kizaki M; Tamaru J
    Leuk Lymphoma; 2016; 57(1):161-6. PubMed ID: 25860238
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: produces stable disease but at the cost of high toxicity.
    Warlick ED; Cao Q; Miller J
    Leukemia; 2013 Aug; 27(8):1789-91. PubMed ID: 23446311
    [No Abstract]   [Full Text] [Related]  

  • 57. Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients.
    Tak WY; Ryoo BY; Lim HY; Kim DY; Okusaka T; Ikeda M; Hidaka H; Yeon JE; Mizukoshi E; Morimoto M; Lee MA; Yasui K; Kawaguchi Y; Heo J; Morita S; Kim TY; Furuse J; Katayama K; Aramaki T; Hara R; Kimura T; Nakamura O; Kudo M
    Invest New Drugs; 2018 Dec; 36(6):1072-1084. PubMed ID: 30198057
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
    Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma.
    Moccia AA; Hitz F; Hoskins P; Klasa R; Power MM; Savage KJ; Shenkier T; Shepherd JD; Slack GW; Song KW; Gascoyne RD; Connors JM; Sehn LH
    Leuk Lymphoma; 2017 Feb; 58(2):324-332. PubMed ID: 27347845
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase II trial of vorinostat in advanced melanoma.
    Haas NB; Quirt I; Hotte S; McWhirter E; Polintan R; Litwin S; Adams PD; McBryan T; Wang L; Martin LP; vonMehren M; Alpaugh RK; Zweibel J; Oza A
    Invest New Drugs; 2014 Jun; 32(3):526-34. PubMed ID: 24464266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.